FGF19 and hepatocellular carcinoma: Chuma et al. analyzed the levels of several circulating angiogenic factors (VEGF, fibroblast growth factor 19 FGF19, FGF23, and Ang-2) in 74 Child-Pugh-A patients with advanced HCC at baseline and after 4 weeks of treatment with lenvatinib.